Skip to main content
Signal8

Tevogen Inc. (TVGNW)

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of individuals severely affected by acute COVID-19, as well as a specific group of patients struggling with long COVID. Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey.

Sector: Biological Products, (No Diagnostic Substances)

Tevogen Inc. logo

Tevogen Inc.

NASDAQ:TVGNWSub-class of TVGN
-2.64%$0.0847
CLOSED
AH$0.0880+3.90%vs close
Mkt Cap$5.75M
Float43.58M
O/S67.88M
VOL759K sh
$ Vol$62K
RVOL1.50×
Inst Own-
SI0.2%
EarningsNov 13 · in 4d
Dilution
Tevogen Inc. logoNASDAQ:TVGNWClosed$0.0847-2.64%
FormDescription
13D/A
Beneficial Ownership Report (Active, Amended)
4
4
Statement of Changes in Beneficial Ownership
8-K
5.02
8-K
1.01,2.03,3.02,5.02,9.01
5
8-K
8.01,9.01
1
13D/A
Beneficial Ownership Report (Active, Amended)
13D/A
Beneficial Ownership Report (Active, Amended)
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
8-K
5.02,9.01
4
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
8-K
8.01
2
8-K
5.02,5.03,5.07,9.01
3
S-8
SEC Filing
4
10-Q
Quarterly Report
9
DEF 14A
Definitive Proxy Statement
4
8-K
5.03,9.01
PRE 14A
Preliminary Proxy Statement
4
13D/A
Beneficial Ownership Report (Active, Amended)
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

1-25 of 309

…